Does Rallies show 13F holders for ORGO?

Yes. Rallies tracks hedge fund and 13F ownership data for ORGO, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ORGO research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ORGO. It does not provide personalized investment advice.

ORGO (Organogenesis Holdings Inc. Class A Common Stock) Stock Analysis - Hedge Fund Holdings

Organogenesis Holdings Inc. Class A Common Stock (ORGO) is a publicly traded Healthcare sector company. As of May 21, 2026, ORGO trades at $2.55 with a market cap of $319.11M and a P/E ratio of 15.59. ORGO moved +5.35% today. Year to date, ORGO is -42.18%; over the trailing twelve months it is -21.78%. Its 52-week range spans $2.04 to $7.08. Analyst consensus is neutral with an average price target of $0.00. Rallies surfaces ORGO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ORGO stock?

Hedge funds tracked by Rallies that own ORGO include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Organogenesis Holdings Inc. Class A Common Stock.

ORGO Key Metrics

Key financial metrics for ORGO
Metric	Value
Price	$2.55
Market Cap	$319.11M
P/E Ratio	15.59
EPS	$0.16
Dividend Yield	0.00%
52-Week High	$7.08
52-Week Low	$2.04
Volume	0
Avg Volume	0
Revenue (TTM)	$564.17M
Net Income	$37.03M
Gross Margin	0.00%

Top Hedge Funds Holding ORGO

Exoduspoint Capital holds 276.91K shares of ORGO, changed +0.00% as of Mar 31, 2026.

Latest ORGO News

Organogenesis Q1 Revenue Falls 58% to $36.3M, Loss Widens to $53.2M — May 7, 2026
Organogenesis Completes FDA BLA Submission for ReNu Knee OA Allograft — Apr 28, 2026
Organogenesis Trial Demonstrates Statistically Significant DFU Closure in 12 Weeks — Apr 7, 2026
Organogenesis’ PuraPly AM Shows Statistically Significant Ulcer Closure in 170-Patient Trial — Apr 6, 2026
Organogenesis Plans Rolling BLA Submission for ReNu by End-2025 After FDA Meeting — Apr 6, 2026

Recent ORGO Insider Trades

Leibowitz Arthur S bought 5.00K (~$13.40K) on Mar 9, 2026.
Driscoll Michael Joseph bought 10.00K (~$26.69K) on Mar 9, 2026.
NUSSDORF GLENN H sold 200.00K (~$1.03M) on Dec 16, 2025.

ORGO Analyst Consensus

1 analysts cover ORGO: 0 strong buy, 0 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $0.00.

Common questions about ORGO

Who owns ORGO stock?: Hedge funds tracked by Rallies that own ORGO include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Organogenesis Holdings Inc. Class A Common Stock.
Does Rallies show 13F holders for ORGO?: Yes. Rallies tracks hedge fund and 13F ownership data for ORGO, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ORGO research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ORGO. It does not provide personalized investment advice.